Ad Header



The Pulse of the Pharmaceutical Industry

Boston Scientific’s sales beat on demand for heart devices

Written by: | | Dated: Thursday, July 28th, 2016


Boston Scientific Corp reported better-than-expected quarterly sales as it sold more of its heart devices and revenue from its troubled cardiac rhythm management business increased.

The company also raised its full-year revenue forecast range to $8.27 billion-$8.37 billion from $8.08 billion-$8.23 billion.

The cardiac rhythm management business, which sells pacemakers and defibrillators, had been weighing on Boston Scientific’s results for several months due to the lack of MRI-compatible products.

However, new device approvals in the business helped improve sales in the second quarter, rising 4.5 percent from a year earlier and 18.2 percent from the first quarter to $512 million.

The company reported a net loss of $207 million, or 15 cents per share, for the quarter ended June 30, largely due to litigation charges. The company posted a profit of $102 million, or 8 cents per share, a year earlier.

On an adjusted basis, Boston Scientific earned 27 cents per share, in line with the average analyst estimate, according to Thomson Reuters I/B/E/S.

The company’s net sales rose 15.4 percent to $2.13 billion. Analysts on an average had expected $2.05 billion.



(Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel)

Source: Reuters Health

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

October 2018 Focus: Top 50 Pharma, Company of the Year and more!


Ad Right Bottom